SEGMENT REPORTING - Revenue (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($) segment	Mar. 31, 2023 USD ($)
Segment reporting
Number of operating segments | segment	2
Total net revenues	$ 137,430	$ 106,786
Depreciation and amortization	14,686	14,700
Corporate and other unallocated expenses	48,021	36,468
Operating Income	20,312	9,895
Unrealized gain on investment in equity securities	9,655	0
Interest expense, net	(4,600)	(7,696)
Other expense, net	(32)	(34)
Income Before Income Tax Expense	25,335	2,165
Operating Segments | Generics, Established Brands, and Other
Segment reporting
Total net revenues	100,493	90,456
EBITDA	45,306	38,828
Operating Segments | Rare Disease
Segment reporting
Total net revenues	36,937	16,330
EBITDA	396	(1,251)
Corporate, Non-Segment
Segment reporting
Depreciation and amortization	(14,686)	(14,700)
Corporate and other unallocated expenses	(10,704)	(12,982)
Operating Income	20,312	9,895
Unrealized gain on investment in equity securities	9,655	0
Interest expense, net	(4,600)	(7,696)
Other expense, net	$ (32)	$ (34)